The Indolylcoumarin COUFIN Exhibits Potent Activity Against Renal Carcinoma Cells without Affecting Hematopoietic System

Author(s): Pierre Champelovier, Pascale Barbier, Etienne Daras, Soazig Douillard, Bertrand Toussaint, Virginie Persoon, Veronique Curri, Vincent Peyrot, Sebastien Combes

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 14 , Issue 6 , 2014

Become EABM
Become Reviewer
Call for Editor


The present work describes the anticancer activity of a new indolylcoumarin named COUFIN and more specifically, its efficiency against clear cell renal carcinoma (CCRC). COUFIN inhibited microtubule formation and bound on tubulin to or near the colchicine site. In vitro, COUFIN showed potent anticancer activity on renal carcinoma cells (RCC) both in monolayer (2D culture) (IC50 of 88±8 nM) and multicellular tumor spheroid (3D culture) (IC50 of 180±20 nM). The compound blocked cell cycle transition at G2/M phase, induced a subsequent apoptotic process but did not modulate clonal growth of CFU-GM. On the other hand, the coumarin derivative decreased the activity of P-gp and BCRP but was not substrate for these ABC pumps. In vivo, the indolylcoumarin increased the survival rate after 3 weeks of treatment. Based on the present study, COUFIN was identified as a bifunctional molecule able to inhibit renal carcinoma cells proliferation without being effluxed by ABC proteins. Thus COUFIN could be a promising chemotherapeutic agent for treating tumor cells over-expressing efflux pumps and tumor cells irrigated by vessels lined with endothelial cells responsible of poor distribution of conventional anticancer agents.

Keywords: Apoptosis, Arylcoumarin, cancer, efflux pump, multidrug resistance, tubulin.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 11 June, 2014
Page: [862 - 871]
Pages: 10
DOI: 10.2174/1871520614666140223190829
Price: $65

Article Metrics

PDF: 27